Compare NWE & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWE | LIVN |
|---|---|---|
| Founded | 1923 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.3B |
| IPO Year | 2023 | 2015 |
| Metric | NWE | LIVN |
|---|---|---|
| Price | $73.95 | $78.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 11 |
| Target Price | $74.50 | ★ $90.55 |
| AVG Volume (30 Days) | 544.0K | ★ 584.5K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.59% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.43 | ★ 2.33 |
| Revenue | ★ $1,610,559,000.00 | N/A |
| Revenue This Year | $7.88 | $9.65 |
| Revenue Next Year | $4.61 | $7.11 |
| P/E Ratio | $52.30 | ★ $33.28 |
| Revenue Growth | ★ 6.38 | N/A |
| 52 Week Low | $58.57 | $48.82 |
| 52 Week High | $76.68 | $85.76 |
| Indicator | NWE | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 63.46 | 53.90 |
| Support Level | $68.74 | $77.28 |
| Resistance Level | $75.10 | $82.39 |
| Average True Range (ATR) | 1.77 | 1.99 |
| MACD | 0.45 | 0.37 |
| Stochastic Oscillator | 78.38 | 80.23 |
NorthWestern Energy Group Inc provides electricity and natural gas services in the Upper Midwest and Northwest of the U.S. in the states of Montana, South Dakota, Nebraska, and Yellowstone National Park. The company's primary segments include Electric, which includes the generation, purchase, transmission, and distribution of electricity, and Natural Gas, which includes the production, purchase, transmission, storage, and distribution of natural gas. It uses thermal, wind, hydro, or renewable energy in varying quantities, depending on the location of the facilities, to generate power. The company derives the majority of its revenue from the Electric segment.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.